
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
Lupin Limited reported a strong set of results for the first quarter of financial year 2025–26 (Q1 FY26), with solid growth in both revenue and profitability. For the quarter ended June 30, 2025, the company achieved a 12% year-on-year (YoY) increase in revenue, reaching ₹6163.8 crore, while net profit surged by 52% YoY to ₹1219.1 crore. The company's operating margin also improved significantly, highlighting an efficient cost structure and higher contribution from complex generics.
Revenue: ₹6,163.8 crore, up 12% YoY
EBITDA: ₹1,641.4 crore, up 27.6% YoY; EBITDA margin rose to 26.6%
Net Profit: ₹1,219.1 crore, increased 52.1% YoY
As of 6th August, 2025 Lupin share price was ₹1,851.10
Gross Profit: ₹4,391.9 crore; margin expanded to 71.3%
Other Operating Income: ₹104.5 crore, up 21.6% YoY
Sales Breakdown by Geography:
Region | Revenue (₹ crore) | YoY Growth |
North America | 2,515.5 | 23% |
India | 2,089.4 | 8% |
EMEA | 626.9 | 25% |
APAC | 315.8 | 3% |
LATAM | 173.8 | 17% |
RoW | 199.3 | 29% |
API | 243.1 | 33% |
The quarter witnessed Lupin’s highest consolidated sales in recent years, backed by sustained performance in the US market, steady growth in India, and a sharp rise in the API and EMEA segments.
Metric | Q1 FY26 | Q1 FY25 | YoY Growth |
Net Sales | ₹6,163.8 crore | ₹5,514.3 crore | 11.8% |
EBITDA (excl. Fx) | ₹1,641.4 crore | ₹1,286.4 crore | 27.6% |
EBITDA Margin | 26.6% | 23.3% | +330 bps |
Net Profit | ₹1,219.1 crore | ₹801.3 crore | 52.1% |
R&D Spend | ₹208.6 crore | ₹111.7 crore | +86.7% |
Capex | ₹484.4 crore | ₹350.0 crore | +38.4% |
Quarter-on-quarter (QoQ), net profit increased by 57.8%, while sales rose 10.8%, indicating strong sequential performance.
India Business
Revenue: ₹2,089.4 crore, up 8% YoY
Rx Sales Growth: 8.6% in line with IPM growth
Leading therapeutic areas: Cardiology, Respiratory, Gastrointestinal, and Vitamins-Minerals-Supplements (VMS)
Anti-diabetes growth was modest at 6.8% due to loss of exclusivity in key products
Launched 5 new products; plans 20+ launches in FY26
Chronic therapies contributed ~65% to sales
North America
Revenue: ₹2,515.5 crore, up 23% YoY
Highest quarterly sales since Q4 FY17
Key driver: Launch of Tolvaptan (gJynarque®) with sole 180-day exclusivity
Pipeline includes 49 FTFs (19 exclusive), and 100+ new product launches planned till FY30
Market share of ~4.5% in US generic prescriptions
API Segment
Revenue: ₹243.1 crore, 33% growth YoY
Supported internal formulation needs and external sales
Certified by TGA (Australia) and WHO Geneva during the quarter
Lupin’s Q1 results outperformed broad sector expectations in terms of margin expansion and profit growth. While many Indian pharma companies faced pricing pressure in the US generics market, Lupin’s performance bucked the trend, aided by exclusive launches and a shift toward complex generics.
R&D and capex investments also aligned well with sectoral strategies, focusing on inhalation, injectables, and biosimilars—high-value areas expected to drive long-term growth.
The management highlighted consistent improvement in margins driven by operating leverage, product mix optimisation, and strategic launches. Investments in high-complexity products are expected to further enhance profitability and market share.
Compliance improvements were evident:
Nagpur Unit-II: Received Establishment Inspection Report (EIR) from US FDA
Pithampur Units: Awaiting response review from US FDA after Form 483 issuance
Approvals received from global regulators, including WHO, TGA, and HESSEN (Germany)
Source: Q1 FY25-26 Quarterly Results uploaded on 6th August, 2025, on BSE.
For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading